Healthpeak Properties, Inc. (DOC) P/E Ratio History
ExpensiveTrading at 195.6x vs 5Y avg 49.5x · 100th percentile · Material premium to history · Data 2013–2026
Loading P/E history...
P/E Ratio Analysis
As of June 21, 2026, Healthpeak Properties, Inc. (DOC) trades at a price-to-earnings ratio of 195.6x, with a stock price of $19.56 and trailing twelve-month earnings per share of $0.32.
The current P/E is 295% above its 5-year average of 49.5x. Over the past five years, DOC's P/E has ranged from a low of 20.6x to a high of 167.5x, placing the current valuation at the 100th percentile of its historical range.
Compared to the Real Estate sector median P/E of 24.1x, DOC trades at a 712% premium to its sector peers. The sector includes 174 companies with P/E ratios ranging from 0.7x to 195.6x.
Relative to the broader market, DOC commands a significant premium over the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our DOC DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
DOC Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
DOC P/E vs Peers
Diversified healthcare real estate peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $39B | 151.1 | - | +184% | |
| $145B | 148.7 | - | -11% | |
| $13B | 23.0 | 0.98Best | +25% | |
| $743M | 1.4Lowest | - | +284%Best | |
| $94M | 115.3 | - | -394% | |
| $498M | 225.2 | - | +134% | |
| $2B | 14.4 | - | +24% | |
| $3B | 23.5 | - | -4% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
DOC Historical P/E Data (2013–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $16.43 | $0.32 | 52.1x | +4% |
| FY2025 Q4 | Dec 31 2025 | $16.08 | $0.10 | 167.5x | +235% |
| FY2025 Q2 | Jun 30 2025 | $17.51 | $0.23 | 75.4x | +51% |
| FY2025 Q1 | Mar 31 2025 | $20.22 | $0.40 | 50.9x | +2% |
| FY2024 Q4 | - | $20.27 | $0.35 | 58.4x | +17% |
| FY2024 Q3 | Sep 30 2024 | $22.87 | $0.47 | 48.6x | -3% |
| FY2024 Q2 | Jun 30 2024 | $19.60 | $0.47 | 41.6x | -17% |
| FY2024 Q1 | Mar 31 2024 | $18.75 | $0.36 | 52.8x | +5% |
| FY2023 Q4 | Dec 31 2023 | $19.80 | $0.56 | 35.1x | -30% |
| FY2023 Q3 | Sep 30 2023 | $18.36 | $0.44 | 41.3x | -17% |
| FY2023 Q2 | Jun 30 2023 | $20.10 | $0.97 | 20.6x | -59% |
| FY2023 Q1 | Mar 31 2023 | $21.97 | $1.01 | 21.8x | -57% |
| FY2022 Q4 | Dec 31 2022 | $25.07 | $0.92 | 27.3x | -46% |
| FY2022 Q3 | Sep 30 2022 | $22.92 | $0.96 | 24.0x | -52% |
| FY2022 Q2 | - | $25.91 | $0.41 | 63.8x | +28% |
| FY2022 Q1 | - | $34.33 | $0.79 | 43.7x | -13% |
| FY2021 Q4 | Dec 31 2021 | $36.09 | $0.93 | 39.0x | -22% |
| FY2021 Q3 | - | $33.48 | $1.15 | 29.1x | -42% |
| FY2021 Q2 | Jun 30 2021 | $33.29 | $0.93 | 35.8x | -28% |
| FY2021 Q1 | Mar 31 2021 | $31.74 | $0.51 | 62.0x | +24% |
| FY2020 Q4 | - | $30.23 | $0.78 | 38.7x | -23% |
| FY2020 Q3 | Sep 30 2020 | $27.15 | $0.60 | 45.1x | -10% |
| FY2020 Q2 | - | $27.56 | $0.63 | 43.9x | -12% |
| FY2020 Q1 | - | $23.85 | $0.51 | 47.1x | -6% |
| FY2019 Q4 | - | $34.47 | $0.10 | 356.8x | +613% |
| FY2019 Q3 | Sep 30 2019 | $35.63 | $1.74 | 20.5x | -59% |
| FY2019 Q2 | Jun 30 2019 | $31.98 | $2.04 | 15.7x | -69% |
| FY2019 Q1 | Mar 31 2019 | $31.30 | $2.26 | 13.8x | -72% |
| FY2018 Q4 | Dec 31 2018 | $27.93 | $2.21 | 12.6x | -75% |
| FY2018 Q3 | Sep 30 2018 | $26.32 | $0.35 | 74.2x | +48% |
| FY2018 Q2 | Jun 30 2018 | $25.82 | $0.13 | 200.9x | +302% |
| FY2017 Q4 | Dec 31 2017 | $26.08 | $0.86 | 30.2x | -40% |
| FY2017 Q3 | Sep 30 2017 | $27.83 | $1.11 | 25.0x | -50% |
| FY2017 Q2 | Jun 30 2017 | $31.96 | $1.45 | 22.0x | -56% |
| FY2017 Q1 | Mar 31 2017 | $31.28 | $2.05 | 15.3x | -70% |
| FY2016 Q4 | Dec 31 2016 | $29.72 | $1.33 | 22.3x | -55% |
| FY2015 Q3 | Sep 30 2015 | $37.25 | $0.52 | 71.6x | +43% |
| FY2015 Q2 | - | $36.47 | $0.81 | 45.0x | -10% |
| FY2015 Q1 | - | $43.21 | $0.93 | 46.5x | -7% |
| FY2014 Q4 | Dec 31 2014 | $44.03 | $2.01 | 21.9x | -56% |
| FY2014 Q3 | - | $39.71 | $2.22 | 17.9x | -64% |
| FY2014 Q2 | Jun 30 2014 | $41.38 | $2.19 | 18.9x | -62% |
| FY2014 Q1 | Mar 31 2014 | $38.79 | $2.18 | 17.8x | -64% |
| FY2013 Q4 | - | $36.32 | $2.13 | 17.1x | -66% |
| FY2013 Q3 | Sep 30 2013 | $40.95 | $2.02 | 20.3x | -59% |
Average P/E for displayed period: 50.0x
Full Stock Analysis
Deep dive into DOC consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
13+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
DOC — Frequently Asked Questions
Quick answers to the most common questions about buying DOC stock.
What is DOC's P/E ratio?
Healthpeak Properties, Inc. (DOC) trailing twelve-month P/E ratio is 195.6x, based on TTM diluted EPS of $0.32. The 5-year average P/E is 49.5x and the historical range spans 20.6x to 167.5x.
Is DOC stock overvalued or undervalued?
DOC trades at 195.6x P/E, above its 5-year average of 49.5x. The 100th percentile ranking within the 20.6x–167.5x historical range indicates a premium to historical valuation.
Is DOC stock expensive?
Yes, DOC is expensive relative to its own history. The current P/E of 195.6x is above the 5-year average of 49.5x and also above the Real Estate sector median of 24.1x. The stock sits at the 100th percentile of its 5-year valuation range.
What is DOC's historical P/E range?
Over the past 5 years, DOC's P/E ratio has ranged from 20.6x to 167.5x, with a median of 43.7x and an average of 49.5x. The current P/E of 195.6x places the stock at the 100th percentile of this range. Full historical data spans 2013–2026.
How does DOC's P/E compare to the S&P 500?
DOC trades at 195.6x P/E versus the S&P 500 median of 24.4x. The 702% premium to the market typically reflects higher expected earnings growth or quality.
How does DOC's valuation compare to Real Estate peers?
Healthpeak Properties, Inc. P/E of 195.6x compares to the Real Estate sector median of 24.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is DOC's PEG ratio?
DOC PEG ratio is N/A, based on a P/E of 195.6x and EPS growth of -72.2%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is DOC's earnings yield?
DOC earnings yield is 0.51%, the inverse of its 195.6x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.